Early diagnosis of Gaucher disease in pediatric patients: Proposal for a diagnostic algorithm

Pediatric Blood and Cancer

Volumn 61, Issue 11, 2014, Pages 1905-1909

  Di Rocco, Maja ^a   Andria, Generoso ^b   Deodato, Federica ^c   Giona, Fiorina ^d   Micalizzi, Concetta ^a   Pession, Andrea ^e  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Algorithm; Gaucher disease; Pediatric age

Indexed keywords

GLYCOLIPID;

ALGORITHM; BONE MARROW BIOPSY; CONSENSUS; CYTOPENIA; EARLY DIAGNOSIS; ENZYME ASSAY; ENZYME DEFICIENCY; GAUCHER DISEASE; HUMAN; PRIORITY JOURNAL; REVIEW; SPLENOMEGALY; BIOPSY; BONE MARROW; CHILD; ENZYMOLOGY; PATHOLOGY;

ALGORITHMS; BIOPSY; BONE MARROW; CHILD; EARLY DIAGNOSIS; GAUCHER DISEASE; HUMANS; SPLENOMEGALY;

EID: 84922610517     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25165     Document Type: Review

References (46)

1. Grabowski GA. Phenotype, diagnosis, and treatment of Gaucher's disease. Lancet 2008; 372:1263-1271.
2. Grabowski GA, Petsko GA, Kolodny EH. Gaucher disease. In: The online metabolic & molecular bases of inherited disease (OMMBID) - Part 16: Lysosomal disorders - Chapter 146. McGraw-Hill global education holdings, LLC Inc, New York: 2013. Available online at: http://www.ommbid.com/OMMBID/the_online_metabolic_and_molecular_bases_of_inherited_disease/b/abstract/part16/ch146
3. Dreborg S, Erikson A, Hagberg B. Gaucher disease - Norrbottnian type. I. General clinical description. Eur J Pediatr 1980; 133:107-118.
4. Rosenbloom BE, Weinreb NJ. Gaucher disease: A comprehensive review. Crit Rev Oncog 2013; 18:163-175.
5. Taddei TH, Kacena KA, Yang M, et al. The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 2009; 84:208-214.
6. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160:2835-2843.
7. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2-5 years of treatment: A report from the Gaucher Registry. Am J Med 2002; 113:112-119.
8. Charrow J, Dulisse B, Grabowski GA, et al. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 2007; 71:205-211.
9. Andersson H, Kaplan P, Kacena K, et al. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008; 122:1182-1190.
10. Weinreb N, Taylor J, Cox T, et al. A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol 2008; 83:890-895.
11. Kaplan P, Mazur A, Manor O, et al. Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 1996; 129:149-153.
12. Sims KB, Pastores GM, Weinreb NJ, et al. Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: Results of a 48-month longitudinal cohort study. Clin Genet 2008; 73:430-440.
13. Wenstrup RJ, Kacena KA, Kaplan P, et al. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007; 22:119-126.
14. de Fost M, Hollak CE, Groener JE, et al. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: A 2-center retrospective analysis. Blood 2006; 108:830-835.
15. Hollak C, Maas M, Akkerman E, et al. Dixon quantitative chemical shift imaging is a sensitive tool for the evaluation of bone marrow responses to individualized doses of enzyme supplementation therapy in type 1 Gaucher disease. Blood Cells Mol Dis 2001; 27:1005-1012.
16. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004; 41:4-14.
17. Mistry PK, Cappellini MD, Lukina E, et al. A reappraisal of Gaucher disease-Diagnosis and disease management algorithms. Am J Hematol 2011; 86:110-115.
18. Mistry PK, Sadan S, Yang R, et al. Consequences of diagnostic delays in type 1 Gaucher disease: The need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol 2007; 82:697-701.
19. Di Rocco M, Giona F, Carubbi F, et al. A new severity score index for phenotypic classification and evaluation of responses to treatment in type I Gaucher disease. Haematologica 2008; 93:1211-1218.
20. Di Rocco M, Andria G, Bembi B, et al. Minimal disease activity in Gaucher disease: Criteria for definition. Mol Genet Metab 2012; 107:521-525.
21. Fink A, Kosecoff J, Chassin M, et al. Consensus methods: Characteristics and guidelines for use. Am J Public Health 1984; 74:979-983.
22. International Collaborative Gaucher Group (ICGG). Gaucher Registry. 2010. Annual Report for people affected with Gaucher disease and their families. Available online at: http://www.gaucherlife.co.uk/images/downloads/A5_Gaucher_Patient_2011.pdf
23. Kaplan P, Andersson HC, Kacena KA, et al. The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006; 160:603-608.
24. Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program 2012; 2012:13-18.
25. Kattlove HE, Williams JC, Gaynor E, et al. Gaucher cells in chronic myelocytic leukemia: An acquired abnormality. Blood 1969; 33:379-390.
26. Pandey MK, Rani R, Zhang W, et al. Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease. Mol Genet Metab 2012; 106:310-322.
27. Faden MA, Krakow D, Ezgu F, et al. The Erlenmeyer flask bone deformity in the skeletal dysplasias. Am J Med Genet A 2009; 149A:1334-1345.
28. Carter A, Rajan PS, Deegan P, et al. Quantifying the Erlenmeyer flask deformity. Br J Radiol 2012; 85:905-909.
29. Harris CM, Campbell P. The importance of correct phenotyping in Gaucher disease. J Child Neurol 2007; 22:1056-1057.
30. Mistry PK, Weinreb NJ, Kaplan P, et al. Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis 2011; 46:66-72.
31. Davies EH, Mengel E, Tylki-Szymanska A, et al. Four-year follow-up of chronic neuronopathic Gaucher disease in Europeans using a modified severity scoring tool. J Inherit Metab Dis 2011; 34:1053-1059.
32. Aerts JM, Hollak CE. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 1997; 10:691-709.
33. Costello R, O'Callaghan T, Sébahoun G. Gaucher disease and multiple myeloma. Leuk Lymphoma 2006; 47:1365-1368.
34. Lee RE, Ellis LD. The storage cells of chronic myelogenous leukemia. Lab Invest 1971; 24:261-264.
35. Zidar BL, Hartsock RJ, Lee RE, et al. Pseudo-Gaucher cells in the bone marrow of a patient with Hodgkin's disease. Am J Clin Pathol 1987; 87:533-536.
36. Robak T, Urbańska-Ryś H, Jerzmanowski P, et al. Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen:Diagnostic and therapeutic dilemmas. Leuk Lymphoma 2002; 43:2343-2350.
37. Shenjere P, Roy A, Eyden B, et al. Pseudo-Gaucher cells in multiple myeloma. Int J Surg Pathol 2008; 16:176-179.
38. Saito T, Usui N, Asai O, et al. Pseudo-Gaucher cell proliferation associated with myelodysplastic syndrome. Int J Hematol 2007; 85:350-353.
39. Büsche G, Majewski H, Schlué J, et al. Frequency of pseudo-Gaucher cells in diagnostic bone marrow biopsies from patients with Ph-positive chronic myeloid leukaemia. Virchows Arch 1997; 430:139-148.
40. Links TP, Karrenbeld A, Steensma JT, et al. Fatal respiratory failure caused by pulmonary infi{ligature}ltration by pseudo-Gaucher cells. Chest 1992; 101:265-266.
41. Dunn P, Kuo MC, Sun CF. Pseudo-Gaucher cells in mycobacterial infection: A report of two cases. J Clin Pathol 2005; 58:1113-1114.
42. Bain BJ, Lee L. Pseudo-Gaucher cells in sickle cell anemia. Am J Hematol 2010; 85:435.
43. Cajaiba MM, Reyes-Mugica M. Gaucher or pseudo-Gaucher? The challenge of several diseases colliding in a pediatric patient. Hum Pathol 2009; 40:594-598.
44. Reuser AJ, Verheijen FW, Bali D, et al. The use of dried blood spot samples in the diagnosis of lysosomal storage disorders:Current status and perspectives. Mol Genet Metab 2011; 104:144-148.
45. Lukacs Z, Nieves Cobos P, et al. Dried blood spots in the diagnosis of lysosomal storage disorders:Possibilities for newborn screening and high-risk population screening. Clin Biochem 2011; 44:476.
46. Olivova P, Cullen E, Titlow M, et al. An improved high-throughput dried blood spot screening method for Gaucher disease. Clin Chim Acta 2008; 398:163-164.